SCHEMBL4488404

SCHEMBL4488404

NC1CCN(Cc2ccccc2C(F)(F)F)C1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.56
ALDH1A1 P00352 8/20 0.56
ATM Q13315 2/20 0.56
KMT2A Q03164 2/20 0.54
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
NPSR1 Q6W5P4 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TACR1 P25103 2/20 0.49
TDP1 Q9NUW8 2/20 0.48
RECQL P46063 1/20 0.48
GAA P10253 1/20 0.48
MEN1 O00255 1/20 0.46
DPP4 P27487 2/20 0.46
CHRM1 P11229 1/20 0.46
SIGMAR1 Q99720 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6944191 0.91 KDM4E (0.63) KDM4EALDH1A1ATMKMT2APOLB
Fumaric Acid SCHEMBL4500295 0.89 KDM4E (0.53) KDM4EALDH1A1ATMKMT2AMAPT
Fumaric Acid SCHEMBL4500298 0.89 KDM4E (0.53) KDM4EALDH1A1ATMKMT2AMAPT
SCHEMBL807392 0.81 KDM4E (0.59) KDM4EALDH1A1ATMKMT2APOLB
Cyclopentanamine SCHEMBL5925376 0.80 KDM4E (0.59) KDM4EALDH1A1ATMKMT2APOLB
SCHEMBL15859935 0.80 KDM4E (0.55) KDM4EALDH1A1ATMKMT2APOLB
SCHEMBL3166277 0.79 KDM4E (0.52) KDM4EALDH1A1ATMKMT2APOLB
Hydrochloric Acid SCHEMBL4221800 0.79 ATM (0.55) KDM4EALDH1A1ATMKMT2APOLB
SCHEMBL15859937 0.79 KDM4E (0.63) KDM4EALDH1A1ATMKMT2APOLB
SCHEMBL22613055 0.77 TSHR (0.61) KDM4EALDH1A1ATMKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022130352-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2022-06-23 WO disclosed
US-7619096-B2 3-Aminopyrrolidines as inhibitors of monoamine uptake ELI LILLY AND COMPANY (US) 2009-11-17 US disclosed
US-20060270713-A1 3-Aminopyrrolidines as inhibitors of monoamine uptake ELI LILLY AND COMPANY 2006-11-30 US disclosed
EP-1638934-A1 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2006-03-29 EP disclosed
WO-2005000811-A1 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE ELI LILLY AND COMPANY (US) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270713-A1 3-Aminopyrrolidines as inhibitors of monoamine uptake SLC6A2, SLC6A3, SLC18A2 KDM4E 1943/4885ALDH1A1 249/4885ATM 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.